Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 715

Sort by

Sort Order Select

Journal Articles

How I treat anemia in heart failure

Inder Anand, Pankaj Gupta

Blood (2020) 136 (7): 790–800.

https://doi.org/10.1182/blood.2019004004

Published: 2020

Includes: Supplemental data

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Differential Effects of HIV Protease Inhibitors on Release and Activation of Platelet-Derived TGF-β1: Potential Association with HIV-Linked CVD

Kouzbari Karim, DDS, Gostynska Sandra, MS, Sonia Elhadad, PhD, Dube Pratibha, MS, Jeffrey Laurence, MD, Jasimuddin Ahamed, PhD

Blood (2019) 134 (Supplement_1): 2341.

https://doi.org/10.1182/blood-2019-126225

Published: 2019

Journal Articles

Potentially Modifiable Risk Factors for 30‐Day Readmission in Adults with Sickle Cell Disease: A National Database Study

Manojna Konda, MD, Arya Mariam Roy, MD, Anusha Jillella, MD, Akshay Goel, MD, Appalanaidu Sasapu, MD

Blood (2019) 134 (Supplement_1): 4857.

https://doi.org/10.1182/blood-2019-132215

Published: 2019

Journal Articles

Assessment of Cardiac Abnormalities in Sickle Cell Disease Patients Using Echocardiography

Osama Mukarram, MD, Gian Lima, MD, Samuel Crooks, BA, Min Jung Kim, PhD, Agnes S Kim, MD PhD

Blood (2019) 134 (Supplement_1): 4837.

https://doi.org/10.1182/blood-2019-128390

Published: 2019

Journal Articles

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Selina M. Luger, MD FRCPC, Zhuoxin Sun, PhD, Sanam Loghavi, MD, Hillard M Lazarus, MD, Jacob M. Rowe, MB, BS, Martin S. Tallman, MD, Keith W. Pratz, MD, Mark Litzow, MD

Blood (2019) 134 (Supplement_1): 1309.

https://doi.org/10.1182/blood-2019-128377

Published: 2019

Journal Articles

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Karl M. Kilgore, PhD, Iman Mohammadi, PhD, Amy Schroeder, BPharm, Christie Teigland, PhD, Anna Purdum, PharmD,MS, Gunjan L. Shah, MD

Blood (2019) 134 (Supplement_1): 793.

https://doi.org/10.1182/blood-2019-124364

Published: 2019

Journal Articles

Prediction of Risk for Adverse Pregnancy Outcomes in Women with Sickle Cell Disease

A. Kinga Malinowski, MD MSc, FRCSC, Kevin H. M. Kuo, MDMSc,FRCPC, George A. Tomlinson, PhD BSc, MSc, Richard Ward, MSc, MRCP, FRCPath, Nadine Shehata, MDFRCPC,MSc

Blood (2019) 134 (Supplement_1): 1009.

https://doi.org/10.1182/blood-2019-130087

Published: 2019

Journal Articles

Long-Term Outcome of Children with Acute Leukemia (AL) Given Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)

Pietro Merli, MD, Daria Pagliara, MD PhD, Mattia Algeri, MD, Federica Galaverna, MD, Giuseppina Li Pira, PhD, Valentina Bertaina, PhD, Mauro Montanari, MD, Giovanna Leone, MD, Stefania Gaspari, MD, Michele Massa, MD, Valentina Cirillo, PhD, Maria Giuseppina Cefalo, MD, Simone Biagini, MSc, Marco Becilli, MD, Elia Girolami, MSc, Roberto Carta, MD, Annalisa Ruggeri, MD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 799.

https://doi.org/10.1182/blood-2019-128416

Published: 2019

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2019) 134 (Supplement_1): 781.

https://doi.org/10.1182/blood-2019-125204

Published: 2019

Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 756.

https://doi.org/10.1182/blood-2019-126619

Published: 2019

Journal Articles

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Jeanne Mendell, PhD MPH, Ruth Namuyinga, MD MPH, Hoang Pham, PharmD, Nabil Said, MD MPH, Yibin Wang, PhD, Tsvetomir Mitov, MD, Ben Kim, PharmD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 1372.

https://doi.org/10.1182/blood-2019-121762

Published: 2019

Journal Articles

Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Craig A. Portell, MD, Nolan A Wages, PhD, Brad S. Kahl, MD, Lihua E Budde, MD PhD, Robert W. Chen, MD, Jonathon B. Cohen, MDMS, Gina Petroni, PhD, Michael E. Williams, MD

Blood (2019) 134 (Supplement_1): 1535.

https://doi.org/10.1182/blood-2019-128788

Published: 2019

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Blood (2019) 134 (Supplement_1): 693.

https://doi.org/10.1182/blood-2019-125120

Published: 2019

Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Blood (2019) 134 (Supplement_1): 696.

https://doi.org/10.1182/blood-2019-127954

Published: 2019

Journal Articles

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Jesus G. Berdeja, MD, Tara K. Gregory, MD, Suman Kambhampati, MD, Bertrand M. Anz, III, MD, Stefano R. Tarantolo, MD, Anthony A. Meluch, MD, Jeffrey V. Matous, MD

Blood (2019) 134 (Supplement_1): 603.

https://doi.org/10.1182/blood-2019-130277

Published: 2019

Journal Articles

Late Effects and Subsequent Neoplasms in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Based Analysis Including Impact of Front-Line Regimen Type

Lori S Muffly, MD, Fran Maguire, PhD MPH, Qian Li, MS, Vanessa Kennedy, MD, Theresa H.M. Keegan, PhD MS

Blood (2019) 134 (Supplement_1): 421.

https://doi.org/10.1182/blood-2019-124992

Published: 2019

Journal Articles

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Aaron T. Gerds, MD MS, Michael R. Savona, MD, Bart L. Scott, MD, Moshe Talpaz, MD, Miklos Egyed, Claire N Harrison, Professor, Abdulraheem Yacoub, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Jennifer O'Sullivan, Sarah A Buckley, MD, Diane R. Mould, PhD, Shanthakumar Tyavanagimatt, PhD, Jennifer A. Smith, PhD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 667.

https://doi.org/10.1182/blood-2019-129293

Published: 2019

Journal Articles

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Kristen Pettit, MD, Aaron T. Gerds, MD MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS,PhD, Natasha Joan Curtin, MDFRACP,FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M Ross, MD PhD, Hugh Young Rienhoff, Jr., MD

Blood (2019) 134 (Supplement_1): 556.

https://doi.org/10.1182/blood-2019-123244

Published: 2019

Journal Articles

Prediction of Cardiac Complications in SCD

Alessia Pepe, MD, Laura Pistoia, Maria Rita Gamberini, MD, Silvia Macchi, MD, Francesca Valeria Commendatore, Elena Facchini, MD, Lorella Pitrolo, Mauro Celli, Aurelio Maggio, MD, Paolo Preziosi, Vincenzo Positano, Antonella Meloni, PhD

Blood (2019) 134 (Supplement_1): 1026.

https://doi.org/10.1182/blood-2019-121843

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

How I treat anemia in heart failure

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Differential Effects of HIV Protease Inhibitors on Release and Activation of Platelet-Derived TGF-β1: Potential Association with HIV-Linked CVD

Potentially Modifiable Risk Factors for 30‐Day Readmission in Adults with Sickle Cell Disease: A National Database Study

Assessment of Cardiac Abnormalities in Sickle Cell Disease Patients Using Echocardiography

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Prediction of Risk for Adverse Pregnancy Outcomes in Women with Sickle Cell Disease

Long-Term Outcome of Children with Acute Leukemia (AL) Given Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Late Effects and Subsequent Neoplasms in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Based Analysis Including Impact of Front-Line Regimen Type

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Prediction of Cardiac Complications in SCD

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only